Capricor Therapeutics, Inc.
General ticker "CAPR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $457.5M (TTM average)
Capricor Therapeutics, Inc. follows the US Stock Market performance with the rate: 13.8%.
Estimated limits based on current volatility of 2.4%: low 23.59$, high 24.72$
Factors to consider:
- Total employees count: 102 (+37.8%) as of 2023
- Top business risk factors: Substantial additional funding needed, Significant losses, Cybersecurity threats, Regulatory and compliance, Product development risks
- Current price 87.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.18$, 19.61$]
- 2025-12-31 to 2026-12-31 estimated range: [4.58$, 12.97$]
Financial Metrics affecting the CAPR estimates:
- Positive: with PPE of -11.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.35 <= 0.04
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: negative Industry operating income (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Shareholder equity ratio, % of 85.32 > 64.17
Short-term CAPR quotes
Long-term CAPR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.55MM | $25.18MM | $22.27MM |
| Operating Expenses | $32.25MM | $49.26MM | $64.84MM |
| Operating Income | $-29.70MM | $-24.08MM | $-42.56MM |
| Non-Operating Income | $0.68MM | $1.79MM | $2.10MM |
| R&D Expense | $21.82MM | $36.45MM | $49.97MM |
| Income(Loss) | $-29.02MM | $-22.29MM | $-40.47MM |
| Profit(Loss)* | $-29.02MM | $-22.29MM | $-40.47MM |
| Stockholders Equity | $11.79MM | $22.60MM | $145.46MM |
| Assets | $50.09MM | $58.73MM | $170.48MM |
| Operating Cash Flow | $4.92MM | $-25.60MM | $-40.00MM |
| Capital expenditure | $3.36MM | $2.05MM | $1.54MM |
| Investing Cash Flow | $-35.07MM | $5.11MM | $-116.18MM |
| Financing Cash Flow | $4.87MM | $25.58MM | $152.77MM |
| Earnings Per Share** | $-1.18 | $-0.83 | $-1.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.